TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30224340

Group type: EXPERIMENTAL
Intervention: Iron-labeled bone marrow cell transplants (injected with ferumoxytol nanoparticles)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Unlabeled cell transplants (control group)
Number of subjects: 7
Study: 30224389

Group type: EXPERIMENTAL
Intervention: Survey of patients and their primary informal caregivers every 4 months until patients' death; caregivers followed until 8 weeks postpatient death.
Number of subjects: 250
Study: 30224393

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets prescribed
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets for musculoskeletal pain
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets for fracture
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets for renal colic or abdominal pain
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets for other pain conditions
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg tablets for first 3 days
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Overall opioid consumption
Number of subjects: 627
Study: 30224926

Group type: EXPERIMENTAL
Intervention: Herbal medicine ICH-012 (8 herbal medicines including Hirudo and Tabanus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Herbal medicine ICH-012
Number of subjects: 0
Study: 30225601

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with gemcitabine (GEM) 1000 mg/m² for three cycles followed by gemcitabine-erlotinib and radiotherapy
Number of subjects: 25
Study: 30225844

Group type: EXPERIMENTAL
Intervention: High-dose oral immunotherapy (OIT) with biweekly dose step-up until reaching maximum maintenance dose (MMD) of 5000 mg peanut protein or individual maintenance dose (IMD).
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High-dose oral immunotherapy (OIT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Not applicable (observation only control group)
Number of subjects: 77
Study: 30225949

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Anti-TNF withdrawal
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Serum S100A8/A9 levels
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Serum S100A12 levels
Number of subjects: 137
Study: 30226851

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 847
Study: 30227072

Group type: EXPERIMENTAL
Intervention: MEDI-551, an anti-CD 19 B-cell depleting monoclonal antibody, administered for up to 197 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30227108

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30227144

Group type: EXPERIMENTAL
Intervention: Diasorin Liaison platform assay
Number of subjects: 219

Group type: COMPARATOR
Intervention: LC-MS/MS method
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Diasorin and Roche automated assays
Number of subjects: 219
Study: 30227169

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 217

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 217
Study: 30227842

Group type: EXPERIMENTAL
Intervention: Individual optimal diets developed through linear programming
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Linear programming dietary modeling
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Dietary modeling
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: K-means cluster analysis of optimized diets
Number of subjects: 576
Study: 30227856

Group type: EXPERIMENTAL
Intervention: CPAP therapy at month 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPAP therapy at month 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPAP therapy at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline factors (headaches, psychological symptoms, arterial hypertension, EuroQol visual analog scale)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up variables (Epworth and average nighttime hours)
Number of subjects: 0
Study: 30227864

Group type: EXPERIMENTAL
Intervention: tDCS plus finger tracking training
Number of subjects: 6
Study: 30227886

Group type: EXPERIMENTAL
Intervention: 15 mg/kg tremelimumab at 90 day intervals
Number of subjects: 360
Study: 30227893

Group type: EXPERIMENTAL
Intervention: brachyury-targeted antitumor vaccine, TGF-β TRAP/anti-PD-L1 antibody, IL-15 agonist, IDO1 inhibitor
Number of subjects: 0
Study: 30227964

Group type: EXPERIMENTAL
Intervention: Asymptomatic AF patients
Number of subjects: 9319

Group type: COMPARATOR
Intervention: Symptomatic AF patients
Number of subjects: 9319
Study: 30228248

Group type: EXPERIMENTAL
Intervention: BNP levels
Number of subjects: 2797
Study: 30228251

Group type: EXPERIMENTAL
Intervention: Cuffless PTT device (TestBP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cuff-based standard BP device (RefBP)
Number of subjects: 71
Study: 30228904

Group type: EXPERIMENTAL
Intervention: 14 days of clarithromycin treatment
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2199
Study: 30229280

Group type: EXPERIMENTAL
Intervention: CT-P13 at a starting dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks up to week 46, with increased dose of 1.5 mg/kg for inadequate response from week 14 to week 46.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CT-P13 treatment
Number of subjects: 12
Study: 30230252

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programs
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1150
Study: 30230263

Group type: EXPERIMENTAL
Intervention: Inhaled batefenterol
Number of subjects: 0
Study: 30230947

Group type: EXPERIMENTAL
Intervention: JE-CV booster dose in children
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: JE-CV single dose primary vaccination in toddlers
Number of subjects: 2
Study: 30231626

Group type: EXPERIMENTAL
Intervention: erenumab 70 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: erenumab 140 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: topiramate
Number of subjects: 9

Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 9

Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 9
Study: 30231665

Group type: EXPERIMENTAL
Intervention: 0.4 mg [14C]-MT-1303
Number of subjects: 0
Study: 30231851

Group type: EXPERIMENTAL
Intervention: Everolimus (switch from cyclosporine)
Number of subjects: 797

Group type: COMPARATOR
Intervention: Cyclosporine (standard regimen)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced-exposure cyclosporine
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 797

Group type: COMPARATOR
Intervention: Standard CNI therapy
Number of subjects: 797
Study: 30231854

Group type: EXPERIMENTAL
Intervention: MRI and CTC assessments during radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of CTCs and MRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of MR imaging and CTC assessments
Number of subjects: 0
Study: 30231890

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg every 4 weeks, with additional doses on days 8 and 15 of cycle 1.
Number of subjects: 100
Study: 30231899

Group type: EXPERIMENTAL
Intervention: Selenium (Se) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30231923

Group type: EXPERIMENTAL
Intervention: Patients with T2DM
Number of subjects: 111
Study: 30232114

Group type: EXPERIMENTAL
Intervention: Anticipated condition (visual information provided prior to jump)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Unanticipated condition (visual information provided 400 msec prior to landing)
Number of subjects: 70

Group type: COMPARATOR
Intervention: ACL-reconstructed individuals
Number of subjects: 70

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 70
Study: 30232146

Group type: EXPERIMENTAL
Intervention: Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30232224

Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg twice daily for 7 days every 21 days
Number of subjects: 60
Study: 30232415

Group type: EXPERIMENTAL
Intervention: Intrabone single UCB transplant
Number of subjects: 23
Study: 30232558

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg orally once daily until disease progression or unacceptable toxicity
Number of subjects: 25
Study: 30232587

Group type: EXPERIMENTAL
Intervention: BMT Roadmap
Number of subjects: 39
Study: 30232616

Group type: EXPERIMENTAL
Intervention: Intraoperative probe-based confocal laser endomicroscopy (pCLE) with near-infrared illumination and indocyanine green as contrast agent.
Number of subjects: 21
Study: 30232735

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Oral ketamine
Number of subjects: 248
Study: 30233062

Group type: EXPERIMENTAL
Intervention: Acoustic stimulation using subjects' own name
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acoustic stimulation using music and noise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: QEEG index in specific stimulation states
Number of subjects: 14
Study: 30233140

Group type: EXPERIMENTAL
Intervention: nimesulide/pantoprazole (100 mg/20 mg) twice daily for 14 days
Number of subjects: 490

Group type: COMPARATOR
Intervention: naproxen/esomeprazole magnesium (500 mg/20 mg) twice daily for 14 days
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: nimesulide/pantoprazole
Number of subjects: 490

Group type: COMPARATOR
Intervention: naproxen/esomeprazole magnesium
Number of subjects: 490
Study: 30233802

Group type: EXPERIMENTAL
Intervention: Pirfenidone 801 mg three times daily for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30233808

Group type: EXPERIMENTAL
Intervention: Salbutamol (900 µg)
Number of subjects: 36
Study: 30233812

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab (both dosing regimens)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30234000

Group type: EXPERIMENTAL
Intervention: Fitbit-Plus (activity trackers + weekly emails)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fitbit-Only (activity trackers only)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fitbit-Plus vs. Fitbit-Only
Number of subjects: 120
Study: 30234149

Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg twice daily after reduction from 10 mg)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg twice daily)
Number of subjects: 178

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Tofacitinib and mycophenolic acid combination
Number of subjects: 178
Study: 30234404

Group type: EXPERIMENTAL
Intervention: FMCA + A (fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FMCA + A
Number of subjects: 16

Group type: COMPARATOR
Intervention: FMC-A (fludarabine, mitoxantrone, cyclophosphamide followed by alemtuzumab)
Number of subjects: 16
Study: 30234410

Group type: EXPERIMENTAL
Intervention: Hair cortisol concentration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current literature on hair cortisol
Number of subjects: 0
Study: 30234419

Group type: EXPERIMENTAL
Intervention: HAT TRICK program (12 weekly sessions promoting healthy eating, active living, and social connectedness)
Number of subjects: 23
Study: 30234539

Group type: EXPERIMENTAL
Intervention: Abdominal accelerometer
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nasal capnometer
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nasal pressure transducer
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oronasal thermistor
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Peritracheal microphone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Transpulmonary electrical impedance
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Photoplethysmography
Number of subjects: 7
Study: 30234617

Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (APDs)
Number of subjects: 683
Study: 30235235

Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil 10 mg
Number of subjects: 10
Study: 30235661

Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence perfusion imaging using indocyanine green (ICG) after graft creation and thoracic pull-up
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ICG angiography (ICGA)
Number of subjects: 70
Study: 30235940

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) adherence measured by time-to-refill
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Caregiver education level (secondary or higher)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Caregiver education level (elementary education only)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) adherence
Number of subjects: 420
Study: 30236025

Group type: EXPERIMENTAL
Intervention: α-1 antitrypsin (AAT) therapy, administered as multiple repeated infusions (up to 36) over a long-term period (up to 5 years)
Number of subjects: 0
Study: 30236149

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 50

Group type: COMPARATOR
Intervention: Self-monitored exercise
Number of subjects: 50
Study: 30236247

Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging after successful sciatic block
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging after failed sciatic block
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging for predicting successful sciatic block
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BFI increase of the big toe at 10 min after sciatic block
Number of subjects: 63
Study: 30236252

Group type: EXPERIMENTAL
Intervention: Intraoperative ventilation with high tidal volume (8.8 ml/kg) and low PEEP, without recruitment manoeuvres.
Number of subjects: 2012
Study: 30236390

Group type: EXPERIMENTAL
Intervention: Late ventricular arrhythmias (VAs) in LVAD recipients
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: VT-LVAD score
Number of subjects: 494
Study: 30236749

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400mg at Weeks 0, 2 and 4, then 200mg every 2 weeks
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 77
Study: 30237023

Group type: EXPERIMENTAL
Intervention: ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay
Number of subjects: 503
Study: 30237265

Group type: EXPERIMENTAL
Intervention: Machine learning application in analyzing organ involvement
Number of subjects: 0
Study: 30237305

Group type: EXPERIMENTAL
Intervention: biweekly α
Number of subjects: 0
Study: 30237702

Group type: EXPERIMENTAL
Intervention: Electrical risk score (ERS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (non-survivors)
Number of subjects: 40
Study: 30237899

Group type: EXPERIMENTAL
Intervention: Communication skills training package (KEW) for therapeutic radiographers
Number of subjects: 0
Study: 30238609

Group type: EXPERIMENTAL
Intervention: Type 1 DM patients
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Type 2 DM patients
Number of subjects: 248

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 248
Study: 30238814

Group type: EXPERIMENTAL
Intervention: E2 vaginal insert 4µg
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: E2 vaginal insert 10µg
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 30239219

Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop (HCL) system (MiniMed™ 670G)
Number of subjects: 29
Study: 30239252

Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposome injection (VSLI) 2.25 mg/m²
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposome injection (VSLI)
Number of subjects: 44
Study: 30239559

Group type: EXPERIMENTAL
Intervention: Psyllium fiber (median dose of ∼10.2 g)
Number of subjects: 1924
Study: 30239831

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AKAP13
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of ERK
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of p38 MAPK
Number of subjects: 0
Study: 30239866

Group type: EXPERIMENTAL
Intervention: NIR (Nitrogen Isotope Ratio)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: CIR (Carbon Isotope Ratio)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Model of animal protein intake based on NIR, CIR, and participant characteristics
Number of subjects: 153
Study: 30240327

Group type: EXPERIMENTAL
Intervention: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in arm A (BRCA1/2 mutated)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in arm B (unselected)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in patients with BRCA2 mutations
Number of subjects: 89
Study: 30240401

Group type: EXPERIMENTAL
Intervention: Severe asthma smokers/ex-smokers (SAs/ex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-smokers (SAn)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current smokers with severe asthma (CSA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ex-smokers with severe asthma (ESA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-smokers with severe asthma (NSA)
Number of subjects: 0
Study: 30240471

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 1200 mg daily for 6 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 24
Study: 30240852

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg, orally once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care EGFR TKI (gefitinib 250 mg or erlotinib 150 mg, orally once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care EGFR TKI
Number of subjects: 0
Study: 30240937

Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galcanezumab 5, 50, 120, and 300 mg subcutaneously every 4 weeks, twice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30241271

Group type: EXPERIMENTAL
Intervention: Opioids (90.7% of patients), with 42.2% receiving weak opioids and 57.8% receiving strong opioids.
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Patients reporting sleep disturbance due to pain.
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Patients reporting problems with pain/discomfort, usual activities, mobility, and anxiety/depression.
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Oral morphine equivalents prescribed (30 mg median daily dose for morphine and tramadol).
Number of subjects: 465
Study: 30241526

Group type: EXPERIMENTAL
Intervention: Proteogenomic characterization and integrative genomic analysis; methods included whole exome and transcriptome sequencing and single nucleotide polymorphism array profiling.
Number of subjects: 6
Study: 30241550

Group type: EXPERIMENTAL
Intervention: sCD163
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Kupffer cell activation
Number of subjects: 29
Study: 30241562

Group type: EXPERIMENTAL
Intervention: Xue-Fu-Zhu-Yu Capsule (XFZYC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30241561

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (normal saline injection)
Number of subjects: 102
Study: 30242306

Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1), given intravenously every 3 weeks until unacceptable toxic effects or loss of clinical benefit
Number of subjects: 116
Study: 30242736

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (200 mg once daily for 6 days)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Linezolid (600 mg twice daily for 10 days)
Number of subjects: 389
Study: 30242747

Group type: EXPERIMENTAL
Intervention: Sedation according to an algorithm promoting alternatives to continuous infusion of midazolam or propofol (intervention group)
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Usual sedation practices (control group)
Number of subjects: 1174

Group type: EXPERIMENTAL
Intervention: Sedation according to an algorithm (intervention group)
Number of subjects: 1174
Study: 30242790

Group type: EXPERIMENTAL
Intervention: High-pressure non-invasive ventilation (NIV) with mean inspiratory positive airway pressure: 27 ± 3 cm H2O
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 20
Study: 30242826

Group type: EXPERIMENTAL
Intervention: Frailty syndrome (assessed with Clinical Frailty Scale ≥ 5 points)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Acute mode of admission
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 272
Study: 30242831

Group type: EXPERIMENTAL
Intervention: Fast metabolizers (n = 65)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Slow metabolizers (n = 71)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both fast and slow metabolizers
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: CYP2A6 normal genotype (n = 82)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: CYP2A6 reduced genotype (n = 42)
Number of subjects: 136
Study: 30243203

Group type: EXPERIMENTAL
Intervention: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: KINARM robot assessments
Number of subjects: 70
Study: 30243299

Group type: EXPERIMENTAL
Intervention: Goserelin (GnRHα) followed by human menopausal gonadotropin (hMG) and human chorionic gonadotropin (hCG)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (10 patients without treatment)
Number of subjects: 35